Acurx Pharmaceuticals (ACXP) Income from Continuing Operations (2024 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Income from Continuing Operations came in at 1680982.0 in Q1 2026, up 21.79% YoY from 1380281.66 in Q1 2025, and down 6.51% on a QoQ basis from 1578276.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 3 years of Income from Continuing Operations data on file, last reported at 1680982.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 21.79% year-over-year to 1680982.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7498327.0 (up 37.66% YoY) and the FY2025 annual result came in at 7966538.0, up 44.12% from the prior year.
- Income from Continuing Operations slipped to 1680982.0 in Q1 2026, from 1578276.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1578276.0 in Q4 2025 to a low of 4121826.0 in Q2 2024.
- A 3-year average of 2440919.88 and a median of 2197736.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 46.25% — and 2026, when it increased 21.79%.
- Tracing ACXP's Income from Continuing Operations over 3 years: stood at 2936416.0 in 2024, then surged by 46.25% to 1578276.0 in 2025, then slipped by 6.51% to 1680982.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1680982.0 (Q1 2026), 1578276.0 (Q4 2025), and 1992790.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | -2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.25 Mn |
| Mar 31, 2026 | -1.68 Mn |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | -1.99 Mn |
| Jun 30, 2025 | -2.25 Mn |
| Mar 31, 2025 | -2.15 Mn |
| Dec 31, 2024 | -2.94 Mn |
| Sep 30, 2024 | -2.82 Mn |
| Jun 30, 2024 | -4.12 Mn |